1. Premalignant gastric lesions in patients included in National colorectal cancer screeningBojan Tepeš, Maja Šeruga, Miroslav Vujasinović, Dejan Urlep, Liljana Ljepovic, Nataša Brglez Jurecic, Alenka Forte, Anita Kek-Ljubec, Miha Skvarč, 2018, original scientific article Abstract: Background. Gastric cancer is the fifth most common malignancy in the world with almost one million new cases annually. Helicobacter pylori infection causes 89% of all gastric cancers. Premalignant lesions (atrophy and intestinal metaplasia) develop after several decades of inflammation. Secondary prevention with gastroscopy is possible, but it is costly and has a low compliance rate. Alternative procedures like serology testing for pepsinogen I and II and pepsinogen I/II ratio are available to select patients for surveillance gastroscopies. Patients and methods. In seven outpatient endoscopic units, 288 patients (154 men; 53.5%), average age 60.68 years, tested positive in National colorectal cancer screening programme SVIT, were included in the study. Gastropanel (BioHit, Finland) was used as a serologic biopsy method. Results. We found 24 patients (12 men, mean age 63.7 years) with pepsinogen (pepsinogen I/II < 3 and/or pepsinogen I < 30 %g/L). Premalignant changes were found on gastric biopsies in 21 patients (7.3% incidence). Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) % 1 was found in 20 patients; Operative Link for Gastritis Assessment (OLGA) % 1 was found in 19 patients. Combined accuracy for preneoplastic lesions in Gastropanel positive patients was 87.5%. H. pylori seropositivity was found in 219 patients (76%). Only 24% of our population had normal results. Conclusions. Gastropanel test has proven to be a reliable non-invasive test for advanced gastric preneoplastic lesions that can select patients for further gastroscopy. We found high H. pylori seropositivity in older age groups in Slovenia.
Keywords: Helicobacter pylori, gastropanel, atrophy, Slovenia, intestinal metaplasia, gastric cancer, SVIT
Published in DiRROS: 02.07.2024; Views: 103; Downloads: 29
 Full text (318,07 KB) |
2. |
3. 11. izobraževalni dan programa ZORA z mednarodno udeležbo : virtualni kongres, 17. november 2021 : zbornik prispevkov2021, proceedings of professional or unreviewed scientific conference contributions Keywords: neodzivnice, program Svit, program DORA, LBTI+, nosečnice, predrakave spremembe, incidence, umrljivost, zborniki, elektronske knjige
Published in DiRROS: 15.03.2022; Views: 866; Downloads: 504
Full text (6,29 MB)
This document has many files! More... |
4. 33. onkološki vikend : državni presejalni programi v onkologiji danes, jutri : zbornik : Ljubljana, 9. oktober 2020, Domus Medica2020, not set Keywords: presejalni programi, nacionalni programi, program ZORA, program DORA, program Svit, perspektivni razvoj, zborniki
Published in DiRROS: 15.03.2021; Views: 1359; Downloads: 474
Full text (5,94 MB) |
5. |
6. Kaj sporoča prenovljeni evropski kodeks proti raku2015, proceedings of professional or unreviewed scientific conference contributions Keywords: zborniki, DORA, ZORA, SVIT, promocija zdravja, zdravstvena vzgoja, neoplazme, preprečevanje, Evropski kodeks proti raku
Published in DiRROS: 13.03.2020; Views: 2239; Downloads: 714
Full text (4,05 MB) |
7. |
8. Program SVIT - presejanje za raka na debelem črevesu in dankiDominika Novak-Mlakar, Tatjana Kofol-Bric, Jožica Maučec Zakotnik, 2015, published professional conference contribution Keywords: NIJZ, SVIT, rak, onkologija, debelo črevo, danka
Published in DiRROS: 17.09.2019; Views: 2120; Downloads: 660
Full text (251,56 KB) |
9. |
10. Presejanje za raka na debelem črevesu in danki - program SVITDominika Novak-Mlakar, Matej Bračko, Jožica Maučec Zakotnik, Marjeta Keršič-Svetel, Tanja Metličar, 2013, professional article Abstract: Po podatkih Registra raka se incidenca raka na debelem črevesu in danki v Sloveniji od leta 1961 povečuje. Največ primerov bolezni se odkrije, ko je ta v napredovali obliki. V obdobju 2005 - 2009 je bil rak na debelem črevesu odkrit v lokalno omejeni obliki le v 12,3 % in rak danke le v 14,9 %. Posledice se kažejo kot visoka stopnja umrljivosti, slaba kakovost življenja bolnikov in visoki stroški zdravljenja. V skladu s priporočili Evropskega sveta in Evropskimi smernicami za zagotavljanje kakovosti v presejanju za raka na debelem črevesu in danki se je v Sloveniji leta 2009 vzpostavil Državni program presejanja in zgodnjega odkrivanja predrakavih sprememb in raka na debelem črevesu in danki – Program Svit. Pozitivni učinki programa so se pokazali že po izvedbi prvega presejalnega kroga.
Keywords: rak (medicina), program SVIT, danka, črevesje, diagnostika
Published in DiRROS: 31.08.2018; Views: 2994; Downloads: 880
Full text (355,97 KB) |
